Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066636 · ClinicalTrials.gov registry record · Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,428
- Enrollment target
NCT02066636 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,428 participants.
The verdict
NCT02066636, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,428 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,428 participants |
| Start Date | 2014-04-09 |
| Est. Completion | 2021-10-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066636
The ClinicalTrials.gov registry entry for NCT02066636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02066636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02066636 about?
NCT02066636 is a clinical study titled "A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen". The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
What is the current status of trial NCT02066636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,428 participants. The study started on 2014-04-09. Estimated completion is 2021-10-06.
What interventions are being tested in trial NCT02066636?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02066636?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.